Tolvaptan for autosomal dominant polycystic kidney disease
Page last updated: 24 March 2022
Drug utilisation sub-committee (DUSC)
October 2021
Abstract
Purpose
To compare predicted and actual utilisation of tolvaptan for autosomal dominant polycystic kidney disease, as requested by DUSC at its June 2021 meeting.
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
Tolvaptan was PBS listed 1 January 2019.
Data Source / methodology
Data extracted from the PBS database maintained by Department of Health, processed by Services Australia were used for analyses.
Key Findings
- There were 362 and 500 patients treated with tolvaptan during the first and second year of listing respectively, which was lower than estimated.
- There were 2,323 and 4,421 tolvaptan prescriptions dispensed during the first and second year of listing respectively, which was lower than estimated.
- The most common age group of patients initiating tolvaptan treatment was 45-49 years old (17.7% of patients), and overall, there was a similar gender ratio of female and male initiating patients.
- The data were too immature to analyse the time on tolvaptan treatment, the median treatment duration was not reached by 30 June 2021.
- The most common dosing regimen were patients only supplied the lowest split dose of 45 mg + 15 mg tablets (43.8%).
Full Report
